RO1 GM74217 Lang Li (PI)                                                                                                                                                   04/01/2005 – 03/31/2011

NIHGMS                                                                                                                                                                                         

Bayesian tools for physiologically-based pharmacokinetics models in drug-drug interaction research. The aim of this study is to develop computational tools to analyze and predict drug-drug interactions.

Role:  Principal Investigator                                                                                                   

UO1 GM61373 Flockhart (PI)                                                                                                                                                05/01/2005 – 07/31/2011

NIGMS

Pharmacogenetics Research Network and Knowledge Base

The goals of the project are (1) to determine the variability in the contributions of three genetically polymorphic enzymes (CYP2C9, CYP2D6 and CYP3A) to tamoxifen metabolism in human liver microsomes and in isolated human hepatocytes, (2) to test the hypothesis that CYP2D6, CYP3A or CYP2C9 genetics alter the pharmacokinetics of tamoxifen and its metabolites in a clinical trial in patients being prescribed tamoxifen as an adjuvant, (3) to test the hypothesis that metabolic pharmacogenetics influence the efficacy of tamoxifen through analysis of tamoxifen concentrations and metabolic genotypes in patients enrolled in the NSABP-P1 trial, and (4) to test the hypothesis that genetics alter the toxicity of tamoxifen.

Role: Core-leader (Biostatistics Core)

P50 CA113001 Tim Huang (PI)                                                                                                                                             03/01/2010 – 02/29/2015

NCI

Interrogating Epigenetic Changes in Cancer Genomes

The goal of this project is to use novel microarray-based and computational approaches for comprehensive profiling of genetic and epigenetic alterations in breast and ovarian cancer.

Role:  Core-leader (Computational Biology Core), Co-PI (project 1)

RO1 GM078501-02 Desta Zeruesenay  (PI)                                                                                                                       07/01/2007--06/30/2012                 

NIGMS                                                                                                                                                                                                                                                 

CYP2B6 genetic variations and drug interactions.

Goals:  The goal of this grant is to determine the impact of CYP2B6genetic polymorphism on substrate drug metabolism and drug interactions

Role: co-investigator.

R01 CA85289 Nephew, Kenneth (PI)                                                                                                                                       04/01/2008-03/31/2013

NCI                                                                                                       

DNA Methylation and Ovarian Cancer

Role: Bioinformatician/Biostatistician

UL1RR025761-01 Anantha Shekhar (PI)                                                                                                                             05/01/2008--04/30/2013

NCRR                               Title: Indiana Clinical and Translational Sciences Institute

To establish a new institute that facilitates clinical and translational biomedical research across the state of Indiana.  This is an institute established by the CTSA to Indiana and Purdue Universities.

Role: Biomedical Informatics Coordinator of the Indiana Biobank                  

RC1 (Renbarger)                                                                                                                                                                         09/30/2009-09/29/2011

Developing a Prediction Model for Vincristine-Induced Peripheral Neuropathy Study in Children with Cancer

Role:      Bioinformatician

KG090959 Susan G. Komen Breast Cancer Foundation,

Bryan Schneider (PI)                                                                                                                                                                 08/08/2009--08/07/2014

Comprehensive Biomarker Discovery Project for Bevacizumab in Breast Cancer

Role: Bioinformatician

U10 HD063094-01 David Flockhart (PI)                                                                                                                                12/01/2009--11/30/2014

Title:  Indiana PREGMED

Goals:  This grant is designed to use a novel approach to determine how pharmacokinetics of candidate selective serotonin reuptake inhibitors changes during pregnancy and to determine whether these changes affect SSRI efficacy.  The central hypothesis of this application is that SSRI metabolism increases during pregnancy resulting in a decrease in patient exposure to the SSRI and subsequent worsening of depressive symptoms and depression scores during pregnancy. Through this effort, we will bring  the expertise of highly skilled and experienced investigators within a strong Division of Clinical Pharmacology, including its broad expertise in drug analysis, pharmacokinetic modeling and clinical pharmacogenomics to the study of drugs in pregnant women and to the OPRU network.

Role: co-investigator

PROSPECT (AHRQ)                                                                                                                                                                12/01/2010 – 11/30/2013

(PI Callaghan C., Overhage M.)

Integrate medical informatics and pharmacogenetics capacities to evaluate treatments for Alzheimer’s disease.

(Role: Bioinformatician)